Such shSRCIN1 cotransfection was sufficient to partially reverse the observed reductions in NSCLC cell viability following miR-657 inhibitor transfection (Figure 7(b)), and EdU uptake assays similarly indicated that miR-657 inhibitors impaired the proliferation of both A549 and NCI-H1650 cells, while SRCIN1 knockdown blunted this effect (Figures 7(c) and 7(d)). This evidence concerns the gene SRCIN1 and non-small cell lung carcinoma.